@Article{096504016X14575597858654,
AUTHOR = {Guo-ying Zhang,  Ai-hua Liu, Guo-min Li, Jian-rong Wang},
TITLE = {HPIP Silencing Prevents Epithelial–Mesenchymal Transition Induced by  TGF-β1 in Human Ovarian Cancer Cells},
JOURNAL = {Oncology Research},
VOLUME = {24},
YEAR = {2016},
NUMBER = {1},
PAGES = {33--39},
URL = {http://www.techscience.com/or/v24n1/56608},
ISSN = {1555-3906},
ABSTRACT = {Hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP/PBXIP1) is a nucleocytoplasmic shuttling protein, and its expression is associated with cancer aggressiveness. However, the role of 
HPIP in ovarian cancer is still unclear. Here, we aimed to clarify the role of HPIP in epithelial–mesenchymal 
transition (EMT) process of ovarian cancer cells, stimulated by transforming growth factor (TGF)-β1. In this 
study, we found that HPIP was highly expressed in ovarian cancer cells, and TGF-β1 treatment induced HPIP 
expression in ovarian cancer cells. In addition, knockdown of HPIP suppressed TGF-β1-induced EMT and 
migration/invasion in ovarian cancer cells. Moreover, knockdown of HPIP significantly blocked the phosphorylated pattern of both PI3K and Akt induced by TGF-β1 in SKOV3 cells. In conclusion, the present study 
showed that HPIP silencing might prevent TGF-β1-induced EMT in ovarian cancer cells. Thus, HPIP may be 
a potential therapeutic target for the treatment of ovarian cancer.},
DOI = {10.3727/096504016X14575597858654}
}